The Journal of Pediatrics
Volume 150, Issue 3 , Pages 229-234.e1 , March 2007

Neurosensory Impairment after Surgical Closure of Patent Ductus Arteriosus in Extremely Low Birth Weight Infants: Results from the Trial of Indomethacin Prophylaxis in Preterms

Received 14 April 2006 ,Revised 5 October 2006 ,Accepted 8 November 2006.

References 

  1. Victorian Infant Collaborative Study Group. Surgery and the tiny baby: sensorineural outcome at 5 years of age. J Paediatr Child Health. 1996;32:167–172
  2. Doyle LW Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks’ gestation: refining the prognosis. Pediatrics. 2001;108:134–141
  3. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344:1966–1972
  4. Schmidt B, Asztalos EV, Roberts RS, Robertson CMT, Sauve RS, Whitfield MF, et al. Impact of BPD, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the Trial of Indomethacin Prophylaxis in Preterms. JAMA. 2003;289:1124–1129
  5. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82:527–532
  6. An international classification of retinopathy of prematurity. Pediatrics. 1984;74:127–133
  7. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity (II. The classification of retinal detachment). Arch Ophthalmol. 1987;105:906–912
  8. Bayley N. Bayley scales of infant development: manual. 2nd ed. San Antonio, Tex: The Psychological Corp, Harcourt Brace & Co; 1993;
  9. Brooks JM, Travadi JN, Patole SK, Doherty DA, Simmer K. Is surgical ligation of patent ductus arteriosus necessary? (The Western Australian experience of conservative management). Arch Dis Child Fetal Neonatal Ed. 2005;90:F235–F239
  10. Palder SB, Schwartz MZ, Tyson KR, Marr CC. Management of patent ductus arteriosus: a comparison of operative v pharmacologic treatment. J Pediatr Surg. 1987;22:1171–1174
  11. Trus T, Winthrop AL, Pipe S, Shah J, Langer JC, Lau GY. Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. J Pediatr Surg. 1993;28:1137–1139
  12. Perez CA, Bustorff-Silva JM, Villasenor E, Fonkalsrud EW, Atkinson JB. Surgical ligation of patent ductus arteriosus in very low birth weight infants: is it safe?. Am Surg. 1998;64:1007–1009
  13. Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, Custer MD. Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg. 2003;38:492–496
  14. Merritt TA, White CL, Jacob J, Kurlinski J, Martin J, DiSessa TG, et al. Patent ductus arteriosus treated with ligation or indomethacin: a follow-up study. J Pediatr. 1979;95:588–591
  15. Robie DK, Waltrip T, Garcia-Prats JA, Pokorny WJ, Jaksic T. Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight?. J Pediatr Surg. 1996;31:1134–1137
  16. Koehne PS, Bein G, Alexi-Meskhishvili V, Weng Y, Buhrer C, Obladen M. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med. 2001;29:327–334
  17. Cassady G, Crouse DT, Kirklin JW, Strange MJ, Joiner CH, Godoy G, et al. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. N Engl J Med. 1989;320:1511–1516
  18. Levitsky S, Fisher E, Vidyasagar D, Hastreiter AR, Bennett EJ, Raju TNK, et al. Interruption of patent ductus arteriosus in premature infants with respiratory distress syndrome. Ann Thorac Surg. 1976;22:131–137
  19. Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr. 1978;93:647–651
  20. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983;102:895–906
  21. Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2003;CD003951
  22. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283:70–74
  23. Simpson JM, Evans N, Gibberd RW, Heuchan AM, Henderson-Smart DJ. Analysing differences in clinical outcomes between hospitals. Qual Saf Health Care. 2003;12:257–262
  24. Arbuckle TE, Sherman GJ. An analysis of birth weight by gestational age in Canada. CMAJ. 1989;140:157–160165

 Supported by the Medical Research Council of Canada MT-13288. US centers were supported in part by grants from the National Institute of Child Health and Human Development (D U10 HD21364, U10 HD27851, U10 HD21373, U10 HD27881; M01 RR 00997, U10 HD27880; M01 RR 00070, U10 HD21385, U10 HD27904, U10 HD34216). INDOCID P.D.A. was donated by Merck Frosst.

PII: S0022-3476(06)01108-5

doi: 10.1016/j.jpeds.2006.11.039

The Journal of Pediatrics
Volume 150, Issue 3 , Pages 229-234.e1 , March 2007

Article Tools

* Image Usage & Resolution